Hubei Goto Biopharm Co.,Ltd. (SHE:300966)
China
· Delayed Price · Currency is CNY 27.40
+2.39 (9.56%)
Apr 30, 2026, 1:55 PM CST
Hubei Goto Biopharm Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2018 |
| Market Capitalization | 2,878 | 2,266 | 1,859 | 2,648 | 3,112 | 4,729 | Upgrade
|
| Market Cap Growth | 48.18% | 21.86% | -29.78% | -14.93% | -34.18% | - | Upgrade
|
| Enterprise Value | 4,175 | 3,527 | 2,838 | 3,321 | 3,500 | 4,781 | Upgrade
|
| Last Close Price | 25.01 | 19.69 | 16.13 | 22.95 | 26.98 | 40.79 | Upgrade
|
| PE Ratio | - | - | - | 115.10 | 77.42 | 60.37 | Upgrade
|
| PS Ratio | 4.75 | 3.74 | 3.47 | 4.68 | 5.15 | 8.00 | Upgrade
|
| PB Ratio | 3.17 | 2.49 | 1.83 | 2.59 | 3.17 | 5.71 | Upgrade
|
| P/TBV Ratio | 3.73 | 2.93 | 2.13 | 2.94 | 3.52 | 6.07 | Upgrade
|
| P/OCF Ratio | 70.14 | 55.22 | - | 38.86 | - | 81.52 | Upgrade
|
| EV/Sales Ratio | 6.89 | 5.82 | 5.29 | 5.86 | 5.79 | 8.09 | Upgrade
|
| EV/EBITDA Ratio | 51.01 | 43.12 | 100.45 | 62.18 | 50.18 | 55.11 | Upgrade
|
| EV/EBIT Ratio | - | - | - | 123.29 | 77.00 | 74.15 | Upgrade
|
| Debt / Equity Ratio | 1.43 | 1.43 | 1.12 | 0.77 | 0.79 | 0.20 | Upgrade
|
| Debt / EBITDA Ratio | 15.88 | 15.88 | 39.68 | 14.25 | 10.60 | 1.84 | Upgrade
|
| Net Debt / Equity Ratio | 1.33 | 1.33 | 0.98 | 0.59 | 0.32 | -0.06 | Upgrade
|
| Net Debt / EBITDA Ratio | 14.84 | 14.84 | 35.05 | 11.31 | 4.54 | -0.56 | Upgrade
|
| Net Debt / FCF Ratio | -9.68 | -9.68 | -2.98 | -1.77 | -0.73 | 1.47 | Upgrade
|
| Asset Turnover | 0.22 | 0.22 | 0.21 | 0.25 | 0.37 | 0.59 | Upgrade
|
| Inventory Turnover | 1.22 | 1.22 | 1.12 | 1.09 | 1.16 | 1.56 | Upgrade
|
| Quick Ratio | 0.34 | 0.34 | 0.44 | 0.61 | 1.26 | 1.37 | Upgrade
|
| Current Ratio | 0.94 | 0.94 | 0.95 | 1.27 | 2.11 | 2.58 | Upgrade
|
| Return on Equity (ROE) | -8.49% | -8.49% | -3.11% | 2.12% | 4.37% | 11.41% | Upgrade
|
| Return on Assets (ROA) | -0.74% | -0.74% | -0.35% | 0.74% | 1.73% | 4.00% | Upgrade
|
| Return on Invested Capital (ROIC) | -1.58% | -1.63% | -0.81% | 1.84% | 4.38% | 8.12% | Upgrade
|
| Return on Capital Employed (ROCE) | -1.70% | -1.70% | -0.70% | 1.50% | 3.00% | 7.30% | Upgrade
|
| Earnings Yield | -2.55% | -3.24% | -1.48% | 0.87% | 1.29% | 1.66% | Upgrade
|
| FCF Yield | -4.35% | -5.53% | -17.87% | -12.88% | -13.88% | -0.70% | Upgrade
|
| Dividend Yield | - | - | - | 0.07% | - | 0.33% | Upgrade
|
| Payout Ratio | - | - | - | 26.49% | 66.92% | 9.67% | Upgrade
|
| Buyback Yield / Dilution | 0.29% | 0.29% | 0.05% | -0.13% | -8.77% | -22.87% | Upgrade
|
| Total Shareholder Return | 0.29% | 0.29% | 0.05% | -0.06% | -8.77% | -22.54% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.